2014
A Targeted Next‐Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice
Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A Targeted Next‐Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. The Oncologist 2014, 19: 453-458. PMID: 24710307, PMCID: PMC4012963, DOI: 10.1634/theoncologist.2013-0377.Peer-Reviewed Original ResearchConceptsBreast cancerGenomic alterationsV-akt murine thymoma viral oncogene homolog 1Stage IV cancerMetastatic breast cancerActionable genomic alterationsPotential treatment optionOncogene homolog 1Primary tumor biopsiesCancer-related genesClinical Laboratory Improvement AmendmentsDependent kinasesMedian sequencing depthGene fusionsSequencing depthBase substitutionsHER2 mutationsHomolog 1Actionable alterationsTargetable alterationsTreatment optionsClinical trialsHER2 amplificationMetastatic cancerTumor biopsies
2012
Use of next-generation sequencing (NGS) to detect high frequency of targetable alterations in primary and metastatic breast cancer (MBC).
Pusztai L, Yelensky R, Wang B, Avritscher R, Symmans W, Lipson D, Palmer G, Moulder S, Stephens P, Wu Y, Cronin M. Use of next-generation sequencing (NGS) to detect high frequency of targetable alterations in primary and metastatic breast cancer (MBC). Journal Of Clinical Oncology 2012, 30: 10559-10559. DOI: 10.1200/jco.2012.30.15_suppl.10559.Peer-Reviewed Original ResearchMetastatic breast cancerClinical trialsNext-generation sequencingNeedle biopsyBreast cancerGenomic alterationsClinical treatment optionsHER2 gene amplificationPatient selection approachAdjuvant therapyTargetable alterationsTreatment optionsPIK3CA mutationsNovel agentsERBB2 alterationsInvestigational drugsTherapeutic implicationsCancer-related genesBiopsyPredictive valueProspective testingNGS profilingDriver mutationsTherapyCancer